News
RMD
228.80
-0.82%
-1.89
J.P. Morgan Keeps Their Buy Rating on Resmed (RMD)
TipRanks · 1h ago
ResMed initiated with an Overweight at JPMorgan
TipRanks · 16h ago
Canaccord Genuity Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
TipRanks · 1d ago
Mizuho Securities Sticks to Their Buy Rating for Resmed (RMD)
TipRanks · 2d ago
ResMed price target lowered to $255 from $300 at Evercore ISI
TipRanks · 2d ago
Weekly Report: what happened at RMD last week (0406-0410)?
Weekly Report · 2d ago
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Ord Minnett
TipRanks · 3d ago
ResMed Price Target Cut to $340.00/Share From $345.00 by Citigroup
Dow Jones · 6d ago
ResMed Is Maintained at Buy by Citigroup
Dow Jones · 6d ago
Citigroup Maintains Buy on ResMed, Lowers Price Target to $340
Benzinga · 6d ago
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Citi
TipRanks · 04/08 23:39
ResMed Insider Selling Raises Questions On Management Conviction And Valuation
Simply Wall St · 04/08 18:24
I Shared 42 Sell Ratings In 2019. Here Is How They Have Performed Long-Term.
Seeking Alpha · 04/07 16:24
Weekly Report: what happened at RMD last week (0330-0403)?
Weekly Report · 04/06 10:10
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
Barchart · 04/01 15:05
ResMed (RMD) Valuation Check After Recent Share Price Weakness
Simply Wall St · 03/31 08:18
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
NASDAQ · 03/30 14:17
Weekly Report: what happened at RMD last week (0323-0327)?
Weekly Report · 03/30 10:10
ResMed Earnings Preview: What to Expect
Barchart · 03/30 07:27
Resmed: Strong Market Position and Financial Profile Offer Upside Amid Overstated GLP‑1 and Competitive Risks
TipRanks · 03/23 23:36
More
Webull provides a variety of real-time RMD stock news. You can receive the latest news about Resmed through multiple platforms. This information may help you make smarter investment decisions.
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.